loader image
Saturday, September 30, 2023
92.6 F
McAllen
We Welcome your Press Release
- Advertisement -

New Alzheimer’s Drug Receives Full FDA Approval

Translate to Spanish or other 102 languages!

The medication, which is called lecanemab, was designed to reduce amyloid beta plaque in the brain. Image for illustration purposes
The medication, which is called lecanemab, was designed to reduce amyloid beta plaque in the brain. Image for illustration purposes

Mega Doctor News

- Advertisement -

CLEVELAND CLINIC – According to the Centers for Disease Control and Prevention (CDC), an estimated 6.5 million Americans are living with Alzheimer’s disease, which does not have a cure.

However, researchers are hopeful about a new medication that was recently approved by the Food and Drug Administration (FDA) for people with early-stage disease.

“When we say Alzheimer’s, it’s a large spectrum, so there are very early stages to very advanced dementia,” said Babak Tousi, MD, neurogeriatrician for Cleveland Clinic. “So, at this point, there are no findings supporting the use of this medication for people with moderate to late-stage dementia. This is for people in the very early stages of the disease.”

- Advertisement -

The medication, which is called lecanemab, was designed to reduce amyloid beta plaque in the brain.

Amyloid beta plaque has been linked to Alzheimer’s disease.

Dr. Tousi explained that the medication does not treat symptoms of the disease but rather helps to slow the progression of it.

As far as success rates go, results from an 18-month clinical trial showed participants who received the medication had a 27 percent reduction in amyloid beta plaque.

- Advertisement -

Dr. Tousi said that number may sound small, but he believes it’s a good place to start.

“It seems we have achieved some treatment. We can affect the disease trajectory. It is a small benefit, but it’s still a benefit,” he said. “We can slow it down and I think it’s one of many to come down the road to hopefully target it, so that’s the biggest step for us.”

Documented side effects for the medication included micro-hemorrhages and edema, which is accumulation of fluid in brain tissue.

Editor’s note: Dr. Tousi is a paid scientific advisor for Biogen and Eisai.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Partnership for COVID-19 Mental Wellness Recovery Efforts, Nov. 1-3 and March 4-6

Consortium will be held at Radisson Hotel in McAllen and consists of two parts. The first part begins November 1 - 3, 2023 and the second part on March 4 - 6, 2024.

World Leaders Commit to New Targets to End Tuberculosis

The targets include reaching 90% of people with TB prevention and care services, using a WHO-recommended rapid test as the first method of diagnosing TB; providing social benefit packages to all people with TB; licensing at least one new TB vaccine; and closing funding gaps for TB implementation and research by 2027. 

Dr. Sujan Gogu, Triple Board-Certified Physician Specializing in Family, Sports & Pain Medicine Joins DHR Health

As the sole triple board-certified physician specializing in these disciplines in the Rio Grande Valley, Dr. Gogu is deeply committed to medical education.

A Milestone for Community Health: Texas Mission of Mercy RGV Successfully Hosts Inaugural Free Dental Clinic

The seriousness of the dental health crisis in South Texas, an area with a population of about 870,000 and significant poverty rates, wasn't lost on the organizers.
- Advertisement -
×